A phase II study of cyclophosphamide as a 24-hr infusion in advanced non-small cell lung cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108032
Title:
A phase II study of cyclophosphamide as a 24-hr infusion in advanced non-small cell lung cancer.
Authors:
Smith, David B; Thatcher, Nick; Steward, William P; Brear, G; Carroll, K
Abstract:
Twenty patients with progressive non-small cell lung cancer who had received no prior chemotherapy were treated with 24-hr infusions of cyclophosphamide at a dose of 2.5 g/m2. The median number of courses administered was three (range one to six). There was one PR and one CR, an overall response rate of 10% (95% confidence limits 2-32%). A further six patients experienced excellent relief of distressing symptoms, unresponsive to other measures, as a result of the chemotherapy. The median survival for the 20 patients was 18.5 weeks (range 4-75 weeks). The median leukocyte nadir count was 1.1 X 10(9)/1 and median platelet nadir count 226 X 10(9)/1. There were no episodes of cystitis and gastrointestinal toxicity was moderate. This study has not shown any advantage for the infusion schedule over conventional bolus regimens, but further dose escalation or more prolonged infusion times may improve results.
Affiliation:
Department of Medical Oncology, Christie Hospital, Manchester M20 9BX, U.K.
Citation:
A phase II study of cyclophosphamide as a 24-hr infusion in advanced non-small cell lung cancer. 1986, 22 (4):435-7 Eur J Cancer Clin Oncol
Journal:
European Journal of Cancer & Clinical Oncology
Issue Date:
Apr-1986
URI:
http://hdl.handle.net/10541/108032
DOI:
10.1016/0277-5379(86)90109-4
PubMed ID:
3732350
Type:
Article
Language:
en
ISSN:
0277-5379
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSmith, David Ben
dc.contributor.authorThatcher, Nicken
dc.contributor.authorSteward, William Pen
dc.contributor.authorBrear, Gen
dc.contributor.authorCarroll, Ken
dc.date.accessioned2010-07-21T10:18:51Z-
dc.date.available2010-07-21T10:18:51Z-
dc.date.issued1986-04-
dc.identifier.citationA phase II study of cyclophosphamide as a 24-hr infusion in advanced non-small cell lung cancer. 1986, 22 (4):435-7 Eur J Cancer Clin Oncolen
dc.identifier.issn0277-5379-
dc.identifier.pmid3732350-
dc.identifier.doi10.1016/0277-5379(86)90109-4-
dc.identifier.urihttp://hdl.handle.net/10541/108032-
dc.description.abstractTwenty patients with progressive non-small cell lung cancer who had received no prior chemotherapy were treated with 24-hr infusions of cyclophosphamide at a dose of 2.5 g/m2. The median number of courses administered was three (range one to six). There was one PR and one CR, an overall response rate of 10% (95% confidence limits 2-32%). A further six patients experienced excellent relief of distressing symptoms, unresponsive to other measures, as a result of the chemotherapy. The median survival for the 20 patients was 18.5 weeks (range 4-75 weeks). The median leukocyte nadir count was 1.1 X 10(9)/1 and median platelet nadir count 226 X 10(9)/1. There were no episodes of cystitis and gastrointestinal toxicity was moderate. This study has not shown any advantage for the infusion schedule over conventional bolus regimens, but further dose escalation or more prolonged infusion times may improve results.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAdult-
dc.subject.meshAged-
dc.subject.meshCyclophosphamide-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshHumans-
dc.subject.meshInfusions, Intra-Arterial-
dc.subject.meshLung Neoplasms-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.titleA phase II study of cyclophosphamide as a 24-hr infusion in advanced non-small cell lung cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Christie Hospital, Manchester M20 9BX, U.K.en
dc.identifier.journalEuropean Journal of Cancer & Clinical Oncologyen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.